HANALL BIOPHARMA
HanAll Biopharma is World’s Best Bio Pharma for R&D of New Innovative Medicine Respectful Pharmaceutical Company to Contribute to Health of the World and to Lead Health Improvement of Mankind.
HANALL BIOPHARMA
Social Links:
Industry:
Biotechnology Fitness
Status:
Active
Contact:
306-81-05479
Email Addresses:
[email protected]
Technology used in webpage:
Apache Apache 2.4 Java EE OpenSSL GeoTrust SSL RapidSSL Unix OpenSSL 1.0.1 Apache Tomcat JK LG U Plus
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Bharat Serums and Vaccines
Bharat Serums and Vaccines develops biopharmaceutical products for patient health improvement.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Current Employees Featured
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-04-11 | Turn.bio | HanAll Biopharma investment in Venture Round - Turn.bio | N/A |
| 2021-08-19 | Alloplex Biotherapeutics | HanAll Biopharma investment in Corporate Round - Alloplex Biotherapeutics | 1000 K USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-21 | HanAll Biopharma Appoints Almira Chabi as Chief Medical Officer and Chief Development Officer |
More informations about "HanAll Biopharma"
ABOUT US | HANALL
2002-2019 From a traditional pharmaceutical company to a biopharma company In the early 2000s, HanAll Biopharma boldly underwent a transformation to become a biopharmaceutical company, setting up cutting-edge laboratories in …See details»
HanAll Biopharma - Crunchbase Investor Profile
HanAll Biopharma World’s Best Bio Pharma for R&D of New Innovative Medicine Respectful Pharmaceutical Company.See details»
NEWS ROOM | HANALL
About HanAll Biopharma HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company founded in 1973, with the mission of making meaningful contributions to patients’ …See details»
[JPM2025] HanAll Biopharma’s US partner says its drug is …
Jan 15, 2025 Immunovant is a U.S. partner of Korean drug development company HanAll Biopharma and is in clinical development of batoclimab (IMVT-1401 or HL161 in HanAll’s …See details»
Hanall Pharmaceutical International, Inc. - Drug pipelines, Patents ...
About HanAll Biopharma HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company with a presence in Korea, the USA, Japan, and Indonesia with a mission of making …See details»
Hanall Biopharma : Organization of Investor Relations Event
Nov 24, 2021 Company Profile Hanall Biopharma Co Ltd is a Korea-based company principally engaged in the manufacture and distribution of synthetic pharmaceuticals and …See details»
HanAll pulls plug on Harbour BioMed’s batoclimab deal over …
Mar 18, 2025 HanAll Biopharma has ended its licensing deal with Harbour BioMed over the autoimmune treatment HL161 (batoclimab), accusing the Chinese biotech of failing to meet …See details»
ABOUT US | HANALL
Founded in 1973, HanAll Biopharma has been at the forefront of scientific innovation, consistently striving to evolve and adapt for the benefit of patients. A significant milestone was achieved in 1974 when HanAll proudly introduced …See details»
HanAll sticks with batoclimab in Asia as Immunovant drops US …
6 days ago When HanAll Biopharma handed over rights to its experimental antibody drug in 2017, it was banking on a global breakthrough. Batoclimab, designed to lower harmful …See details»
HANALL BIOPHARMA terminates license agreement with Harbor …
Mar 18, 2025 HANALL BIOPHARMA entered into a contract with Harbor BioMed in 2017, granting exclusive development and business rights for batoclimab in the Greater China …See details»
HanAll Biopharma - Contacts, Employees, Board Members
HanAll Biopharma World’s Best Bio Pharma for R&D of New Innovative Medicine Respectful Pharmaceutical Company.See details»
HanAll Biopharma receives Orphan Drug Designation in Japan for ...
HanAll Biopharma received Orphan Drug Designation (ODD) from the Ministry of Health, Labor and Welfare (MHLW) in Japan for Batoclimab, an anti-FcRn treatment being developed for a …See details»
Hanall Biopharma verwerft 3,2 Miljard Won aan eigen aandelen
2 days ago Bedrijfsprofiel Hanall Biopharma Co Ltd is een in Korea gevestigde onderneming die zich voornamelijk bezighoudt met de productie en distributie van synthetische geneesmiddelen …See details»
HanAll Biopharma Reports Full-Year 2022 Results and Provides …
Feb 1, 2023 "HanAll continued to transform into innovative global biopharma in 2022 by strengthening clinical development capability and expanding open collaboration network while …See details»
Hanall Biopharma acquisirà 3,2 miliardi di won di azioni proprie
2 days ago Profilo Società Hanall Biopharma Co Ltd è una società con sede in Corea che si occupa principalmente della produzione e distribuzione di prodotti farmaceutici sintetici e …See details»
ABOUT US | HANALL
With humble beginnings as a pharmaceutical producer in 1973, HanAll Biopharma has come a long way, expanding its reach and impact in the Korean market by providing affordable …See details»
HanAll’s Batoclimab Gets Orphan Drug Status in Japan | OBN
Mar 19, 2025 HanAll Biopharma gains Orphan Drug Designation in Japan for Batoclimab, a novel TED treatment, moving closer to market.See details»
NEWS ROOM | HANALL
HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company developing innovative medicines, today reported financial results for the third quarter of 2022 and …See details»
NEWS ROOM | HANALL
About HanAll Biopharma HanAll BioPharma Co., Ltd. (009420.KS), a subsidiary of Daewoong Pharmaceutical Co., Ltd., is a fully integrated biopharmaceutical company based in South …See details»
Simplification for success: Rewiring the biopharma operating model
5 days ago Some organizations have successfully simplified their structures by eliminating duplication between global, regional, and local layers. One biopharma company consolidated …See details»